Acumen Pharmaceuticals Share Price Today

Acumen Pharmaceuticals Q3FY26 Results: Earnings call set for Oct 26, 2026

Acumen Pharmaceuticals will report third quarter financial results on October 26, 2026. Conference call and webcast scheduled for 8:00 am ET on the same day. Company focuses on sabirnetug, a monoclonal antibody targeting Alzheimer's disease. Registration required one day prior to the conference call for dial-in access.

Acumen Pharmaceuticals to speak at Cantor, Citi investor conferences

Acumen Pharmaceuticals will hold fireside chats at Cantor and Citi investor conferences. Cantor session scheduled for September 9, 2026, at 3:55 pm ET. Citi session set for September 10, 2026, at 8:40 am ET. Live webcasts accessible via company website and archived for 90 days.

Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate

Acumen Pharmaceuticals missed Q2 EPS estimates with a loss of $(0.45) per share against an expected $(0.34). The company will discuss these results and its Phase 2 Alzheimer's trial progress during a conference call scheduled for August 12, 2026.

Acumen EBD candidate ACU401 shows 40-fold brain delivery boost

Acumen Pharmaceuticals and JCR Pharmaceuticals presented data at AAIC 2026 demonstrating that EBD candidate ACU401 achieved up to 40-fold greater exposure in the frontal cortex of non-human primates compared to native antibodies, with no hematological safety signals observed. The studies utilized JCR's J-Brain Cargo platform to evaluate transferrin receptor-mediated delivery. Additionally, Acumen shared patient experience data from the ALTITUDE-AD Phase 2 trial, which is evaluating sabirnetug in 542 individuals with early Alzheimer's disease, with topline results expected in late 2026.

Acumen to present EBD technology data at AAIC 2026

Acumen Pharmaceuticals, Inc. will present three key studies at the Alzheimer’s Association International Conference (AAIC) 2026 in London from July 12-15. The presentations will highlight progress with JCR Pharmaceuticals in developing next-generation therapeutics through Enhanced Brain Delivery (EBD) technology and expand the understanding of early symptomatic Alzheimer’s disease. The data will be shared in one oral and two poster presentations covering bispecific antibodies, transferrin receptor-mediated transport, and findings from the ALTITUDE-AD trial population.

Acumen nominates two EBD candidates for Alzheimer's

Acumen Pharmaceuticals nominated ACU301 and ACU401 in its Enhanced Brain Delivery program for Alzheimer's disease, following the exercise of its option with JCR Pharmaceuticals. Preclinical data showed 14-40x higher brain penetration in NHPs compared to native antibodies, with no adverse events observed. IND-enabling activities are ongoing to support a submission in mid-2027.